Left ventricular assist device therapy improves utilization of donor hearts
Keith D. Aaronson, MD, MS*,
Michael J. Eppinger, MD ,
David B. Dyke, MD*,
Susan Wright, BS, RN and
Francis D. Pagani, MD, PhD, FACC,*
* Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
Section of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan, USA
View larger version (21K):
[in a new window]
|
Figure 1 Survival to transplantation of patients in the inotrope group who were potentially eligible for left ventricular assist device (LVAD) therapy and those ineligible because of high-risk factors.
|
|
View larger version (20K):
[in a new window]
|
Figure 2 Survival to transplantation: left ventricular assist device (LVAD) group versus inotrope group.
|
|
View larger version (21K):
[in a new window]
|
Figure 3 Post-transplantation survival: left ventricular assist device (LVAD) group versus inotrope group.
|
|
View larger version (22K):
[in a new window]
|
Figure 4 Post-transplantation survival: inotrope group only (classified into patients who were potential candidates for left ventricular assist device [LVAD] therapy and those considered not eligible because of high-risk factors).
|
|
View larger version (20K):
[in a new window]
|
Figure 5 Post-transplantation survival: left ventricular assist device (LVAD) group vs. patients transplanted as United Network for Organ Sharing status 2.
|
|
View larger version (19K):
[in a new window]
|
Figure 6 Overall survival from the time of bridging to follow-up: left ventricular assist device (LVAD) group versus inotrope group.
|
|
|
